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Abstract
Background: Osteogenesis imperfecta (OI) is a rare genetic bone fragility disorder. 
In the current study, differences between the genotypes and phenotypes of de novo 
and inherited collagen‐related OI were investigated.
Methods: A comparative analysis was performed of the genotypes and phenotypes 
of 146 unrelated inherited and de novo collagen I OI cases from Estonia, Ukraine, 
and Vietnam. Mutational analysis of the subjects and all available parents were per-
formed with Sanger sequencing.
Results: Results showed that 56.16% of the OI cases were caused by de novo patho-
genic variants. The proportion of OI types OI1, OI4, and OI3 among subjects with 
inherited OI was 45.31%, 46.88%, and 7.81%, respectively. Among subjects with de 
novo OI, the proportions of OI types (OI1, OI4, and OI3) were almost equal. Both 
inherited and de novo OI pathogenic variants occurred more often in the COL1A1 
gene than in the COL1A2. The majority of de novo cases were missense pathogenic 
variants, whereas inherited OI was mostly caused by loss of function pathogenic 
variants.
Conclusion: In summary, there were significant differences between the phenotypes 
and genotypes of subjects with de novo and inherited OI. These findings may pro-
mote the further understanding of OI etiology, and assist with diagnostics proce-
dures, as well as with family planning.
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1 |  INTRODUCTION
Osteogenesis imperfecta (OI) is a rare genetic disorder, 
characterized with congenital bone fragility. Prevalence of 
a disorder is estimated as 1/10–20,000 (Marini et al., 2017; 
Van Dijk & Sillence, 2014b). Primary feature of OI is sus-
ceptibility to bone fractures. Secondary features that may be 
present in individuals with OI are as follows: blue sclerae, 
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hearing loss, dentinogenesis imperfecta (DI), joint hypermo-
bility, and short stature (Byers & Steiner, 1992; Marini et al., 
2017; Sillence, Senn, & Danks, 1979). OI is characterized 
by the variability of genotypes and phenotypes, ranging from 
mild osteopenia to perinatal lethality. Sillence OI types corre-
spond to severity of the disorder as follows: type OI1—mild, 
type OI2—lethal, type OI3—severe, type OI4—moderate OI 
(Van Dijk & Sillence, 2014b).
Although there are 20 different recessive genes con-
nected to OI pathology, about 70%–90% of patients with 
OI harbor dominant pathogenic variants in the COL1A1 
(OMIM accession number 120150) and COL1A2 (OMIM 
accession number 120160) genes (Marini et al., 2017; Van 
Dijk & Sillence, 2014a; Womack, 2014). These genes code 
for collagen type I α1 and α2 chains, respectively. Collagen 
type I is an essential structural protein and is the most abun-
dant structural protein in the human body (Gelse, Pöschl, & 
Aigner, 2003). Collagen chains consist of a Gly‐X‐Y trip-
let motifs were every third position is occupied with gly-
cine. The importance of collagen type I is evidenced by 
its high conservation among vertebrates (Bonod‐Bidaud 
& Ruggiero, 2013; Gelse et al., 2003; Stover & Verrelli, 
2011). Collagen type I naturally lacks variation on its ter-
mini, especially in the C‐terminal domain. These termini 
are highly conserved, as they have vital functions, such 
as collagen assembly, transport, and signaling (Stover & 
Verrelli, 2011).
Pathogenic variants in the COL1A1/2 genes cause 
bone fragility, of varying severity. Loss of function (LoF) 
pathogenic variants in COL1A1/2 genes correspond to hap-
loinsufficiency and a collagen type I quantitative defect. 
Dominant negative pathogenic variants (i.e. missense sub-
stitutions) in the collagen type I structure correspond to a 
collagen type I qualitative defect (Ben Amor, Glorieux, & 
Rauch, 2011; Marini et al., 2007; Mendoza‐Londono et al., 
2015; Shapiro, 2014). Gly substitution in the α1/2 chains 
usually correlate with more severe phenotypes. The sever-
ity of a phenotype caused by a dominant negative variant is 
also influenced by position of a substitution (Marini et al., 
2007). Dominant negative pathogenic variants cause the 
synthesis of structurally abnormal collagen, which may 
cause endoplasmic reticulum stress and apoptosis of os-
teoblasts; missense pathogenic variants are therefore more 
deleterious than LoF pathogenic variants (Bonod‐Bidaud & 
Ruggiero, 2013; Lisse et al., 2008). Furthermore, dominant 
negative pathogenic variants appear more frequently, com-
pared to LoF (i.e. frameshift and splice site) pathogenic 
variants, in sporadic genetic diseases (de Ligt, Veltman, & 
Vissers, 2013; Veltman & Brunner, 2012).
Being a rare hereditary disorder of connective tissue, 
OI has traditionally been described as a genetic disorder 
which runs in families. However, both inherited and de 
novo etiology of OI mutations exist. De novo pathogenic 
variants are sporadic variants appearing for the first time 
in a given family. These pathogenic variants are known 
to be more deleterious and to impose a greater load on 
a phenotype than inherited variants (Acuna‐Hidalgo, 
Veltman, & Hoischen, 2016; Veltman & Brunner, 2012). 
In the absence of reproductive selection, de novo patho-
genic variants may cause congenital malformations, spo-
radic syndromes, and rare disorders to remain prevalent 
in a population (Veltman & Brunner, 2012). As noted by 
Acuna‐Hidalgo et al. (2016), de novo variants do not differ 
in prevalence across populations and are the main source 
of neurodegenerative and developmental disorders. With 
the availability of sequencing techniques, our understand-
ing of the role of de novo pathogenic variants in both com-
mon and rare genetic disorders is changing, bringing with 
it increased knowledge about newly arising pathogenic 
variants.
The proportion of de novo OI mutations has previ-
ously been evaluated as being between 35%–60%, which is 
lower than that of other musculoskeletal disorders, such as 
achondroplasia (80%) (Ornitz & Marie, 2002; Osteogenesis 
Imperfecta | 978‐0‐12‐397165‐4 | Elsevier; Trotter & Hall, 
2005).
Although many de novo OI cases have previously been 
described (Maasalu et al., 2015; Steiner, Adsit, & Basel, 
1993; Tongkobpetch et al., 2017; Yin et al., 2018), there 
does not appear, to date, to have been any description or 
comparative analysis between de novo and inherited col-
lagen I pathogenic variants. In the current study, data on 
146 OI patients with either de novo or inherited COL1A1/2 
pathogenic variants were analyzed. Subjects with de novo 
or inherited COL1A1/2 pathogenic variants were compared 
in terms of genotype characteristics and OI phenotype 
severity.
2 |  MATERIALS AND METHODS
2.1 | Ethical compliance
The study was approved with the Ethical Review Committee 
on Human Research of the University of Tartu (Permit no. 
221/M‐34), the ethical review board of Hue University 
Hospital (approval No. 75/CN‐BVYD) and the Sytenko 
Institute of Spine and Joint Pathology of the Ukrainian 
Academy of Medical Sciences.
2.2 | Subjects
Study participants and data were from the OI database of 
the Clinic of Traumatology and Orthopedics, University of 
Tartu, Estonia for research purposes. The database includes 
237 OI families, of Estonian, Ukrainian, and Vietnamese 
origin. Estonian OI patients from the register of Clinic of 
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Traumatology and Orthopedics, Tartu University Hospital 
were enrolled into the database. As a result of collaboration 
between University of Tartu and Hue University of Medicine 
and Pharmacy, Ukrainian Association of Crystal People, 
Sytenko Institute of Spine and Joint Pathology, OI families 
from Ukraine and Vietnam attended an interview and clinical 
examination with researchers from the University of Tartu. 
Patients and their relatives were enrolled into OI database of 
the Clinic of Traumatology and Orthopedics, University of 
Tartu, Estonia. Patients with other skeletal disorders were ex-
cluded from the database. A comparative analysis of de novo 
and inherited OI cases, with OI due to a pathogenic variant in 
either COL1A1 or COL1A2, was performed.
A total number of 146 unrelated subjects, diagnosed with 
OI (types OI1–OI4) and harboring COL1A1/2 pathogenic 
variants participated in the study. Patients were classified as 
OI1–OI4, according to the observed clinical features. Clinical 
and genealogical data were recorded from the patients’ spo-
ken words. Blood samples were obtained (for DNA analysis) 
from all available affected family members and their close 
healthy relatives. COL1A1/2 mutational analysis was per-
formed with Sanger sequencing. Detailed information has 
been reported in previous studies (Binh et al., 2017; Ho Duy 
et al., 2016; Zhytnik et al., 2017). In this current study, the 
cohort was comprised of Estonian (27), Vietnamese (57), and 
Ukrainian (62) OI patients and represented the youngest af-
fected proband of every kindred. Of the cohort, 77 subjects 
were females and 69 were males. The age range of the sub-
jects was from 2 months to 65 years of age.
2.3 | Genealogical analysis and detection of 
de novo cases
Genealogical data were obtained in spoken from subjects 
during oral interviews and included OI family history; fam-
ily consanguinity; history of miscarriages; parental ages; and 
health status (Binh et al., 2017; Zhytnik et al., 2017).
Based on OI family history, the inheritance pattern for every 
kindred was determined. Cases with multiple affected individu-
als across different generations were considered to be inherited 
OI. Cases without a previous OI history were considered to be 
de novo. The inheritance pattern of de novo pathogenic variants 
was identified on the basis of zygosity of the detected patho-
genic variant, and later verified with the mutational analysis in 
parents. Pedigree trees were constructed using the “Kinship2” 
package in the R statistical program v3.3.2. (R team, Austria).
2.4 | Controls
The absence of pathological variants harbored by subjects with 
de novo OI was checked for and confirmed in all available par-
ents. The total number of parent‐child trios was 45. The total 
number of parent–child duos, that is where only one parent was 
available, was 29. No parent samples were available for eight 
of the subjects. In cases where parents’ DNA samples were not 
obtained, the de novo state of the disorder was defined on the 
basis of negative OI history in the family, and the heterozygous 
state of the OI‐causative pathogenic variant.
2.5 | Mutational analysis of healthy parents
3 ml of an EDTA‐preserved whole blood sample of de novo 
probands’ healthy parents was used for genomic DNA pu-
rification, using the Gentra Puregene Blood Kit (Quiagen, 
Germany) in accordance with the manufacturer's protocol, 
and stored at −80°C.
In order to affirm the absence of an OI‐causative patho-
genic variant in healthy parents, Sanger sequencing of 
an exon carrying a subject's pathogenic variant was per-
formed. PCR amplification, Sanger sequencing, and anal-
ysis of the sequencing products were each performed as 
described in previous studies (Ho Duy et al., 2016; Zhytnik 
et al., 2017).
Sequence products were also aligned to the GenBank 
human reference genome sequences of COL1A1 (gDNA 
NG_007400.1, complementary (cDNA) NM_000088.3) and 
COL1A2 (gDNA NG_007405.1, cDNA NM_000089.3). The 
datasets used and analyzed during the study are available 
from the corresponding author upon reasonable request.
2.6 | Statistical analysis
Associations between pathogenic variant nature, and geno-
type, OI type, and phenotype manifestations, were exam-
ined using Fisher's test for categorical variables. Averages 
of continuous variables were compared using the Student's 
t‐test. The threshold of statistical significance was a p‐value 
of <0.05. Statistical analysis of the data was completed with 
R v3.3.2. software (R Team, Austria) (Chen et al., 2012). All 
data analysis and laboratory operations were conducted at the 
University of Tartu, Estonia.
3 |  RESULTS
Of the 146 OI cases analyzed, 82 (56.16%) subjects harbored 
de novo pathogenic variants. The proportion of de novo cases 
among Estonian (EE) OI subjects was 10/27 (37.04%); among 
Ukrainian (UA) 36/62 (58.06%); and among Vietnamese 
(VN) 36/57 (63.16%) (Figures 1 and 2; Table 1). Due to com-
pound heterozygous pathogenic variants in seven patients, 
the total number of analyzed variants was 153. In de novo 
and inherited OI patient group, mean age was 14 and 15‐year‐
olds, respectively.
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3.1 | Phenotypical signatures and 
OI manifestations in collagen I de novo 
pathogenic variants
OI type was significantly associated with the proportion of 
de novo pathogenic variants (p = 0.0002) (Table 1). Among 
those subjects with de novo pathogenic variants, OI types 
OI1, OI3, OI4 were distributed almost evenly; although there 
was a slightly lower amount of type OI1 (26.83%) than of 
types 3 (35.36%) or OI4 (36.59%). In contrast, inherited OI 
was comprised of type OI1 in 45.31% of subjects, type OI3 in 
7.81%, and type OI4 in 46.88%. Both type OI1 and type OI4 
OI were proportionally more common in inherited OI cases 
than in de novo OI. Of the OI type III cases, 85.29% were de 
novo (Figure 3).
Tests on sclera color, hearing loss, and DI did not reveal 
any correlations with pathogenic variant nature (i.e. inherited 
or de novo). The majority of both de novo and inherited OI 
subjects had normal hearing and blue/gray eye sclera (80.49% 
and 84.38% for de novo; and 90.24% and 95.31% for inher-
ited, respectively). The distribution of DI was almost equal 
for de novo (58.54%) and inherited (54.69%) OI subjects.
The number of total fractures (p = 0.0224), as well as frac-
tures per year (p = 0.0014) were significantly higher in sub-
jects with de novo pathogenic variants (means of 21.96 and 
1.74, respectively) than in subjects with inherited OI (means 
of 12.50 and 1.07, respectively). However, when divided by 
types, differences in the number of fractures were only sig-
nificant for fractures per year (mean 2.35, p = 0.0023) for 
subjects with de novo OI type 3, compared to patients with 
inherited OI type 3 (mean 0.95).
3.2 | Proportion, functional type, and  
architecture of de novo and inherited 
COL1A1/2 pathogenic variants
A significant correlation was observed between the 
mutated gene and the nature of the pathogenic variant 
F I G U R E  1  Pedigree trees, photographs, and genotypes of Vietnamese patients with familial (a) and de novo (b) osteogenesis imperfecta. 
1COL1A1 GenBank reference sequence (gDNA NG_007400.1, cDNA NM_000088.3)
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(p = 0.0360). Among de novo cases, COL1A1 pathogenic 
variants comprised 65.91% (58/88), whereas among in-
herited cases, the proportion of COL1A1 pathogenic vari-
ants was higher, at 81.54% (53/65) (Figure 4a; Table 1). 
Half of all identified COL1A1 pathogenic variants were 
de novo (52.25%). The proportion of COL1A2 variants 
was significantly higher in de novo (30/88, or 34.09%) 
than in inherited OI cases (12/65, or 18.46%) (Table 1, 
Figure 4a).
The proportion of de novo or inherited pathogenic vari-
ants was strongly correlated with the functional type of 
the defect (p = 0.0063). A higher proportion of missense 
changes was observed among subjects with de novo patho-
genic variants (68.18%), whereas LoF variants were more 
common among inherited OI (55.38%) (Figure 4b). Of the 
de novo pathogenic variants, 54.55% were Gly substitutions 
(Figure 4c).
Of the 89 missense pathogenic variants, 60 (67.42%) 
were de novo in nature (Table 1). 48/70 (68.57%) of Gly 
substitutions occurred in de novo cases, as did 24/39 
(61.54%) of Gly to Ser substitutions. Differences in the 
proportion of de novo and inherited Gly substitutions were 
significant (p = 0.0139), unlike Gly to Ser substitutions. 
The overall proportion of de novo LoF pathogenic variants 
in the studied cohort was 28/64 (43.75%), of which 16/32 
(50.00%) were splice site pathogenic variants, and 12/32 
(37.50%) were nonsense and frameshift pathogenic vari-
ants (Table 1).
The architecture of the pathogenic variants was also 
investigated. The majority of alterations were nucleotide 
transitions (95, or 62.09%), of which half were comprised 
of the most common G>A (50.66%) pathogenic variants. 
Transversions were observed 38 times (24.84%), of which 
20 cases (13.07%) were with a spread G>T variant. Indels 
appeared 20 times; of which 14 were deletions (9.21%). 
None of these results showed significant differences be-
tween the de novo and inherited OI cases.
Overall, there was no significant correlation between 
the nature of a pathogenic variant (i.e. inherited or de novo) 
and its location. Variants were distributed evenly in the 
COL1A1 gene. The majority of pathogenic variants altered 
the α1 chain region. Interestingly, pathogenic variants of the 
COL1A2 gene only started from the exon 16 and altered the 
α2 chain domain.
4 |  DISCUSSION
The analyses revealed a high proportion of de novo patho-
genic variants in the cohort of OI subjects. These results 
F I G U R E  2  Proportion (%) of de novo mutations by population
37.04%
58.06%
63.16%
56.16%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
Estonian Ukrainian Vietnamese All populations
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correlate with those of Steiner et al. (1993) and lend support 
to the idea that the majority (up to 60%) of OI cases arise as de 
novo pathogenic variants (Steiner et al., 1993). Interestingly, 
the lowest proportion of de novo cases was observed in the 
Estonian OI population. In the authors’ view, this population 
difference may be connected to the milder OI phenotypes of 
the Estonian subjects, which, compared to more severe OI 
phenotypes, have less impact on fitness and do not obstruct 
offspring production.
Osteogenesis imperfecta is a heterogenic skeletal pathol-
ogy with incomplete penetrance and variable severity; the 
proportion of de novo pathogenic variants therefore differs 
according to OI type. Results showed that, among OI3 cases, 
85.29% of pathogenic variants were de novo; this accords 
well with figures for achondroplasia, but was lower than pre-
viously reported rates of OI type 3 (Ornitz & Marie, 2002; 
Osteogenesis Imperfecta | 978‐0‐12‐397165‐4 | Elsevier; 
Trotter & Hall, 2005). This difference may be attributable 
to sample sizes, cohorts’ phenotype characteristics, and/or 
high inter‐ and intrafamilial variability of OI phenotypes. 
Consequently, the same pathogenic variant may cause OI of 
different severities, affecting the relative fitness of the har-
boring individuals. Considering the importance of the cur-
rent topic to family planning and routine genetic testing, the 
T A B L E  1  Characteristics of de novo and inherited OI cases
All patients De novo % Inherited % Total % p‐value
Total 82 56.16 64 43.84 146 100
EE 10 37.04 17 62.96 27 18.49
UA 36 58.06 26 41.93 62 42.47
VN 36 63.16 21 36.84 57 39.04
Sex
Males 34 49.28 35 50.72 69 47.26 0.1338
Females 48 62.34 29 37.66 77 52.74
OI type
OI1 22 (26.83%) 43.14 29 (45.31%) 56.86 51 34.93 0.0002
OI2 1 (1.22%) 100.00 0 0.00 1 0.69
OI3 29 (35.36%) 85.29 5 (7.81%) 14.71 34 23.29
OI4 30 (36.59%) 50.00 30 (46.88%) 50.00 60 41.09
Fractures
Number of total fractures 
(mean)
21.96 12.50 17.81 0.0224
Fractures per year (mean) 1.74 1.07 1.45 0.0014
Genotype
COL1A1a 58 (65.91%) 52.25 53 (81.54%) 47.75 111 72.55 0.0360
COL1A2b 30 (34.09%) 71.43 12 (18.46%) 28.57 42 27.45
Functional type
Loss of function 28 (31.82%) 43.75 36 (55.38%) 56.25 64 41.83 0.0063
Nonsense and frameshift 12 37.50 20 62.50 32
Splice site 16 50.00 16 50.00 32
Missense 60 (68.18%) 67.42 29 (44.62%) 32.58 89 58.17
Gly 48 68.57 22 28.57 70 0.0139
Gly‐Ser 24 61.54 15 38.46 39 0.5796
Architecture of mutations
Transitions 54 56.84 41 43.16 95 62.09 0.6039
Transversions 24 63.16 14 36.84 38 24.84
Indel 10 50.00 10 50.00 20 13.07
Significant p-values marked in bold.
aCOL1A1 GenBank reference sequence (gDNA NG_007400.1, cDNA NM_000088.3). bCOL1A2 GenBank reference sequence (gDNA NG_007405.1, cDNA 
NM_000089.3). 
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F I G U R E  3  (a) Distribution of osteogenesis imperfecta (OI) types in collagen type I de novo and inherited OI. (b) Distribution of OI types in 
subjects with de novo or inherited OI
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F I G U R E  4  (a) Distribution of COL1A11 and COL1A22 mutations for de novo and inherited osteogenesis imperfecta (OI). (b) Functional 
types of mutations in de novo and inherited OI. (c) Collagen defect distributions in de novo and inherited OI. 1COL1A1 GenBank reference 
sequence (gDNA NG_007400.1, cDNA NM_000088.3). 2COL1A2 GenBank reference sequence (gDNA NG_007405.1, cDNA NM_000089.3)
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additional factors which may shape OI phenotype warrant 
further investigation.
4.1 | OI phenotype and etiology of the OI 
pathogenic variant
The most striking result to emerge from the data was that 
types OI1, OI4, and OI3 were distributed among de novo 
cases almost equally (26.83%, 36.59%, and 35.36%, respec-
tively). Relatively lower proportions of types OI1 and OI4, or 
a relatively higher proportion of type OI3 were not observed 
among subjects with de novo pathogenic variants. A possible 
explanation for this result may be that severe sporadic (i.e. 
de novo) variants altering COL1A1/2 genes may generate 
pathologically extreme, lethal phenotypes, which are mostly 
eliminated during early pregnancy; they were therefore not 
captured in this study. Consequently, the various nonlethal 
sporadic OI types arose with relatively similar frequency. 
More pronounced differences in the prevalence of the differ-
ent OI types were observed in the inherited OI cases.
Furthermore, the relative proportions of the milder OI 
forms (i.e. types OI1 and OI4) were lower in de novo cases 
than in inherited cases. It can therefore be hypothesized that 
patients with mild de novo OI are under‐ or misdiagnosed, 
due to a negative OI family history and the variability of clin-
ical characteristics. For example, mild de novo OI forms may 
be misinterpreted as child abuse or assumed to be other skel-
etal dysfunctions.
4.2 | Genotype association with OI 
pathogenic variants’ etiology
As outlined earlier, the majority of collagen type I OI path-
ogenic variants alter the COL1A1 gene. Compared to de 
novo pathogenic variants, the number of inherited COL1A2 
pathogenic variants is significantly lower. Some of the 
COL1A2 gene alterations do not have pathogenic signifi-
cance and may therefore stay undiagnosed. These same 
factors may play a role in the understanding of the lower 
number of COL1A2 pathogenic variants among subjects 
with inherited OI. For example, previous generations may 
have been aware of light bone fragility in the family and 
thus did not connect it with any particular bone condition. 
They may also have lacked diagnostics compared to pa-
tients with de novo OI.
As noted above, a clear distinction was observed in the 
correlations between pathogenic variant type and pathogenic 
variant nature. More than half of inherited OI cases harbored 
LoF (or null‐allele) pathogenic variants, which generally 
lead to milder forms of OI. Interestingly, despite the fact 
that OI types were distributed almost equally among de novo 
OI, the majority of de novo pathogenic variants were struc-
tural. Consequently, the higher prevalence of LoF pathogenic 
variants among inherited OI cases may have been due to the 
higher fitness of mild OI cases.
The results from the analysis of mutational architec-
ture also aligned with those of previous studies (Acuna‐
Hidalgo et al., 2016; de Ligt et al., 2013; Stover & 
Verrelli, 2011). The majority of nucleotide changes in this 
study were G>A transitions, altering the chain domain of 
a protein. Fewer pathogenic variants altered termini re-
gions of collagen type I chains, compared to the chain 
domain. At the same time, the higher overall prevalence 
of transitions compared to transversions may be explained 
by the instability of methylated CpG dinucleotides (CG 
sites) (Acuna‐Hidalgo et al., 2016). Regions rich in CG 
nucleotides are known to be highly expressive. Thus, most 
of the disease‐causing pathogenic variants, including OI, 
happen in coding regions, which are rich in CpG islands.
The implications of de novo pathogenic variants in muscu-
loskeletal disorders is a vital issue for future research, which 
may advance our understanding of the disorders’ nature and 
etiology; highlight risks for both rare and common bone dis-
eases; promote diagnostic approaches; and assist with family 
genetic counseling.
5 |  CONCLUSIONS
The present study analyzed the genotypes and phenotypes of 
de novo and inherited OI cases. Of these, the percentage of de 
novo OI cases was 56.16%. The majority of pathogenic vari-
ants were found to alter the COL1A1 gene. De novo OI cases 
were characterized by a high prevalence of collagen qualita-
tive defects, whereas inherited OI cases were characterized 
by quantitative collagen defects. As found in previous stud-
ies, mild de novo OI appeared to be under‐ or misdiagnosed. 
Further investigation should be focused on the issue of mild OI. 
The proportions of mild and moderate de novo OI cases were 
not lower than the proportion of severe de novo cases. The pro-
portion of COL1A2 variants among subjects with inherited OI 
was significantly lower than for subjects with de novo OI.
These results suggest that there are substantial differences 
between the genotype and phenotype characteristics of de 
novo and inherited OI. The authors believe that more atten-
tion should be given to OI diagnostics, medical awareness, 
and therapy development, as the disorder's prevalence may 
increase as a result of the numerous de novo cases.
The present study only investigated pathogenic variants 
of the COL1A1 and COL1A2 genes. However, with access to 
next‐generation sequencing, the further evaluation of overall 
differences in mutational load between inherited and de novo 
OI patients, and the contribution of these to complex phe-
notype variations, should shed additional light on etiology, 
pathological mechanisms, and the phenotype development of 
OI.
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